The DOI matches its Crossref record.
Patients with a History of Elevated Prostate-Specific Antigen Levels and Negative Transrectal US–guided Quadrant or Sextant Biopsy Results: Value of MR Imaging
Abstract
PURPOSE: To determine the role of magnetic resonance (MR) imaging performed with a combined endorectal body phased-array coil for patients with elevated prostate-specific antigen (PSA) levels or suspicious free-to-total PSA ratios in whom prior transrectal ultrasonographically (US) guided biopsy findings were negative for prostate cancer. MATERIALS AND METHODS: Forty-four patients with PSA levels greater than 4 ng/mL or free-to-total PSA ratios lower than 15% but negative biopsy findings were examined with T1- and T2-weighted MR imaging at 1.5 T with a combined endorectal body phased-array coil. All patients underwent digital rectal examination (DRE) and transrectal US. Thirty-eight patients underwent repeat biopsy after MR imaging. The accuracy of MR imaging for detection of prostate cancer was assessed prospectively. Retrospectively, MR imaging findings were correlated with individual biopsy site findings. MR imaging and biopsy results were correlated by using a cross table to calculate sensitivity, specificity, and positive predictive value (PPV). Retrospective analysis results were evaluated with receiver operating characteristic analysis. A P value of less than.05 indicated significance (chi(2) test according to Pearson). RESULTS: At prospective analysis, MR imaging had a sensitivity of 83% and a PPV of 50% for detection of prostate cancer; these values were 33% and 67%, respectively, for DRE and 33% and 57%, respectively, for transrectal US. At retrospective site-by-site analysis, MR imaging results did not correlate significantly with individual biopsy site findings (P =.126); sensitivity was 65% and PPV was 12%. CONCLUSION: In this patient population, MR imaging has higher sensitivity for detection of prostate cancer than DRE or transrectal US.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
ESUR prostate MR guidelines 2012
Barentsz, J. O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., Rouviere, O., Logager, V., & Fütterer, J. J. (2012) · European Radiology · doi:10.1007/s00330-011-2377-y · Cited by 2,438
Is it time to consider a role for MRI before prostate biopsy?
Ahmed, H. U., Kirkham, A., Arya, M., Illing, R., Freeman, A., Allen, C., & Emberton, M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.18 · Cited by 309
A urologist’s perspective on prostate cancer imaging: past, present, and future
George, A. K., Turkbey, B., Valayil, S. G., Muthigi, A., Mertan, F., Kongnyuy, M., & Pinto, P. A. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0751-6 · Cited by 30
Metadata
- Authors
- Beyersdorff, D., Taupitz, M., Winkelmann, B., Fischer, T., Lenk, S., Loening, S. A., & Hamm, B.
- Venue
- Radiology
- Published
- 2002-09
- Volume
- 224
- Issue
- 3
- Pages
- 701-706
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2039342983
- Cited by
- 178
- References
- 0
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients with a History of Elevated Prostate-Specific Antigen Levels and Negative Transrectal US–guided Quadrant or Sextant Biopsy Results: Value of MR Imaging. https://app.cochat.ai/papers/10.1148/radiol.2243011553
- The paper
- Beyersdorff, D., Taupitz, M., Winkelmann, B., Fischer, T., Lenk, S., Loening, S. A., & Hamm, B. (2002). Patients with a History of Elevated Prostate-Specific Antigen Levels and Negative Transrectal US–guided Quadrant or Sextant Biopsy Results: Value of MR Imaging. Radiology. https://doi.org/10.1148/radiol.2243011553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.